Comment on ‘Augmenting secondary intention healing in dermatological surgery through low-cost interventions’

We respond to an article describing the potential role of topical timolol and botulinum toxin A (BTA) as adjuncts in enhancing wound healing outcomes in dermatological surgery. This article was in response to our article ‘Dermatological surgery: an update on secondary intention healing and adjuncts, part 2’. While preliminary studies have shown promising results, limitations such as small sample sizes, a lack of control groups, and variability in treatment protocols hinder definitive conclusions. Robust, well-powered, randomized controlled trials are necessary to establish efficacy, optimize dosing and assess long-term outcomes before integrating these adjuncts into routine clinical practice.